Vol. 4 No. 4 (2024)
Reimbursement Reviews

Evinacumab (Evkeeza)

decorative image of the issue cover

Published April 17, 2024

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses evinacumab (Evkeeza), 150 mg/mL (345 mg/2.3 mL and 1,200 mg/8 mL) solution in single-dose vials for IV infusion.
  • Indication: As an adjunct to diet and other low-density lipoprotein cholesterol–lowering therapies for the treatment of adult and pediatric patients aged 5 years and older with homozygous familial hypercholesterolemia.